Research programme: submicron respiratory disease therapeutics - iCeutica

Drug Profile

Research programme: submicron respiratory disease therapeutics - iCeutica

Alternative Names: ICE-1202; ICE-1203; ICE-1204

Latest Information Update: 03 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCeutica
  • Class
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 03 Jun 2016 Preclinical trials in Hypersensitivity in USA (Inhalation) (iCeutica pipeline, June 2016)
  • 01 Oct 2014 Research programme: submicron respiratory disease therapeutics - iCeutica is available for licensing as of 01 Oct 2014. http://www.iceutica.com/
  • 01 Oct 2014 Preclinical trials in Asthma in USA (Inhalation) prior to October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top